What are Genentech, Inc.'s marketed drugs?

Top marketed products include Asthma therapies, Cathflo Activase (Alteplase), oseltamivir [Tamiflu], Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf, Raptiva (efalizumab), Tetanus Toxoid Adsorbed Vaccine.

Genentech, Inc.

6 marketed · 12 in Phase 3

Quick facts

Marketed products

Asthma therapies · Respiratory / Immunology
Asthma therapies from Genentech include multiple marketed drugs that work through different mechanisms to reduce airway inflammation and improve lung function in asthma patients.
Cathflo Activase (Alteplase) · Cardiovascular / Interventional
Alteplase is a tissue plasminogen activator (tPA) that converts plasminogen to plasmin, which breaks down fibrin clots.
oseltamivir [Tamiflu]
Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf
Raptiva (efalizumab) · Immunology/Dermatology
Efalizumab blocks the CD11a subunit of lymphocyte function-associated antigen-1 (LFA-1), preventing T-cell activation and migration to the skin.
Tetanus Toxoid Adsorbed Vaccine · Immunology
Tetanus toxoid adsorbed vaccine stimulates the immune system to produce antibodies against tetanus toxin, providing active immunity against tetanus infection.

Phase 3 pipeline

[18F]MK-6240
Analgesic/antipyretic and antihistamine drugs · Pain Management, Allergy/Immunology
This is a combination drug class that reduces pain and fever through analgesic/antipyretic action while simultaneously blocking histamine receptors to reduce allergic responses.
Anti-inflammatory drugs · Immunology
Anti-inflammatory drugs reduce inflammation by inhibiting inflammatory pathways and mediators in the body.
Dexamethasone Mouth Rinse · Immunology / Dermatology / Oral Medicine
Dexamethasone is a corticosteroid that suppresses inflammatory and immune responses by binding to glucocorticoid receptors and reducing production of pro-inflammatory cytokines.
erlotinib HCl · Oncology
Erlotinib is a small-molecule tyrosine kinase inhibitor that blocks the epidermal growth factor receptor (EGFR), preventing cancer cell proliferation and survival.
long-acting beta-agonists · Respiratory / Pulmonology
Long-acting beta-agonists bind to beta-2 adrenergic receptors on airway smooth muscle to cause sustained bronchodilation and improve airflow.
Methyloprednisolone · Other
Ocrelizumab Dose 1 · Immunology
Ocrelizumab is a monoclonal antibody that depletes B cells by binding to CD20, reducing autoimmune-mediated inflammation.
Ocrelizumab Dose 2 and Dose 3 · Immunology
Ocrelizumab is a monoclonal antibody that targets and depletes CD20-positive B cells.
Onartuzumab (MetMab) · Oncology
Onartuzumab is a monoclonal antibody that blocks hepatocyte growth factor (HGF) binding to the MET receptor, inhibiting MET-driven tumor growth and survival signaling.
rhuFab V2 (ranibizumab) · Ophthalmology
Ranibizumab is a recombinant humanized monoclonal antibody fragment that inhibits vascular endothelial growth factor A (VEGF-A).
Tarceva (erlotinib HCl) · Oncology
Tarceva (erlotinib HCl) works by inhibiting the epidermal growth factor receptor (EGFR) tyrosine kinase.

Phase 2 pipeline

Phase 1 pipeline

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: